Sustained Release Oral Formulation for Treatment of Parkinson's Disease

Sustained Release Oral Formulation for Treatment of Parkinson's Disease

Achieving sustained blood levels of carbidopa/levodopa has been a challenge in the treatment of PD and although levodopa remains the most commonly used drug, motor fluctuations remain a major disability especially in advanced Parkinson's disease. The aim of this study is to determine the efficacy of a novel oral carbidopa-levodopa formulation in achieving a sustained blood level of levodopa and carbidopa in normal volunteers.

Inclusion Criteria:

• Normal healthy
• Are 18-65 years of age
• Are not currently taking medications regularly
• Able to fast 6 hours (water allowed)

Exclusion Criteria:

• Pregnancy
• Inability to fast